Immunohistochemical evaluation of solid pseudopapillary tumors of the pancreas: The expression pattern of CD99 is highly unique

Cancer Letters

Volumn 310, Issue 1, 2011, Pages 9-14

  Li, Li ^a   Li, Jinsong ^a   Hao, Chunyan ^a   Zhang, Cuijuan ^a   Mu, Kun ^a   Wang, Yan ^a   Zhang, Tingguo ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

CD99; Differential diagnosis; Immunohistochemistry; Solid pseudopapillary tumor

Indexed keywords

BETA CATENIN; CD99 ANTIGEN; UVOMORULIN;

ACINAR CELL CARCINOMA; ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CELL NUCLEUS; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPLASM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREAS DUCT; PANCREAS SOLID PSEUDOPAPILLARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD; BETA CATENIN; CADHERINS; CARCINOMA, ACINAR CELL; CARCINOMA, NEUROENDOCRINE; CARCINOMA, PANCREATIC DUCTAL; CARCINOMA, PAPILLARY; CELL ADHESION MOLECULES; CELL NUCLEUS; CHILD; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INSULINOMA; MALE; MIDDLE AGED; NEPRILYSIN; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79961128694     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.04.017     Document Type: Article

References (34)

1. V.K. Frantz, Tumors of the pancreas, in: C.W. Blumberg (Ed.), Atlas of Tumor Pathology, Armed Forces Institute of Pathology, Washington, DC, 1959, pp. 32-33.
2. de Castro S.M., Singhal D., Aronson D.C., Busch O.R., van Gulik T.M., Obertop H., Gouma D.J. Management of solid-pseudopapillary neoplasms of the pancreas: a comparison with standard pancreatic neoplasms. World J. Surg. 2007, 31:1130-1135.
3. Yang F., Fu D.L., Jin C., Long J., Yu X.J., Xu J., Ni Q.X. Clinical experiences of solid pseudopapillary tumors of the pancreas in China. J. Gastroenterol. Hepatol. 2008, 23:1847-1851.
4. G. Klöppel, J. Lüttges, D.S. Klimstra, R.H. Hruban, S.E. Kern, G. Adler, Solid-pseudopapillary neoplasm, in: S.R. Hamilton, L.A. Aaltonen (Eds.), World Health Organization Classification of Tumors, Pathology and genetics of tumors of the digestive system, LARC Press, Lyon, 2000, pp. 246-248.
5. Geers C., Moulin P., Gigot J.F., Weynand B., Deprez P., Rahier J., Sempoux C. Solid and pseudopapillary tumor of the pancreas - review and new insights into pathogenesis. Am. J. Surg. Pathol. 2006, 30:1243-1249.
6. Serra S., Chetty R. Revision 2: an immunohistochemical approach and evaluation of solid pseudopapillary tumour of the pancreas. J. Clin. Pathol. 2008, 61:1153-1159.
7. Serra S., Salahshor S., Fagih M., Niakosari F., Radhi J.M., Chetty R. Nuclear expression of E-cadherin in solid pseudopapillary tumors of the pancreas. J. Pancreas 2007, 8:296-303.
8. Notohara K., Hamazaki S., Tsukayama C., Nakamoto S., Kawabata K., Mizobuchi K., Sakamoto K., Okada S. Solid-pseudopapillary tumor of the pancreas: immunohistochemical localization of neuroendocrine markers and CD10. Am. J. Surg. Pathol. 2000, 24:1361-1371.
9. Burford H., Baloch Z., Liu X., Jhala D., Siegal G.P., Jhala N. E-cadherin/beta-catenin and CD10: a limited immunohistochemical panel to distinguish pancreatic endocrine neoplasm from solid pseudopapillary neoplasm of the pancreas on endoscopic ultrasound-guided fine-needle aspirates of the pancreas. Am. J. Clin. Pathol. 2009, 132:831-839.
10. Kim M.J., Jang S.J., Yu E. Loss of E-cadherin and cytoplasmic-nuclear expression of beta-catenin are the most useful immunoprofiles in the diagnosis of solid-pseudopapillary neoplasm of the pancreas. Hum. Pathol. 2008, 39:251-258.
11. Abraham S.C., Klimstra D.S., Wilentz R.E., Yeo C.J., Conlon K., Brennan M., Cameron J.L., Wu T.T., Hruban R.H. Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. Am. J. Pathol. 2002, 160:1361-1369.
12. Min Kim S., Sun C.D., Park K.C., Kim H.G., Lee W.J., Choi S.H. Accumulation of beta-catenin protein, mutations in exon-3 of the beta-catenin gene and a loss of heterozygosity of 5q22 in solid pseudopapillary tumor of the pancreas. J. Surg. Oncol. 2006, 94:418-425.
13. Tang W.W., Stelter A.A., French S., Shen S., Qiu S., Venegas R., Wen J., Wang H.Q., Xie J. Loss of cell-adhesion molecule complexes in solid pseudopapillary tumor of the pancreas. Mod. Pathol. 2007, 20:509-513.
14. Okimura A., Hirano H., Nishigami T., Ueyama S., Tachibana S., Fukuda Y., Yamanegi K., Ohyama H., Terada N., Nakasho K. Immunohistochemical analyses of E-cadherin, beta-catenin, CD44s, and CD44v6 expressions, and Ki-67 labeling index in intraductal papillary mucinous neoplasms of the pancreas and associated invasive carcinomas. Med. Mol. Morphol. 2009, 42:222-229.
15. Audard V., Cavard C., Richa H., Infante M., Couvelard A., Sauvanet A., Terris B., Paye F., Flejou J.F. Impaired E-cadherin expression and glutamine synthetase overexpression in solid pseudopapillary neoplasm of the pancreas. Pancreas 2008, 36:80-83.
16. Chetty R., Serra S. Membrane loss and aberrant nuclear localization of E-cadherin are consistent features of solid pseudopapillary tumour of the pancreas. An immunohistochemical study using two antibodies recognizing different domains of the E-cadherin molecule. Histopathology 2008, 52:325-330.
17. El-Bahrawy M.A., Rowan A., Horncastle D., Tomlinson I., Theis B.A., Russell R.C., Stamp G. E-cadherin/catenin complex status in solid pseudopapillary tumor of the pancreas. Am. J. Surg. Pathol. 2008, 32:1-7.
18. Tanaka Y., Kato K., Notohara K., Hojo H., Ijiri R., Miyake T., Nagahara N., Sasaki F., Kitagawa N., Nakatani Y., Kobayashi Y. Frequent beta-catenin mutation and cytoplasmic/nuclear accumulation in pancreatic solid-pseudopapillary neoplasm. Cancer Res. 2001, 61:8401-8404.
19. Kudo J., Nishiwaki T., Haruki N., Ishiguro H., Shibata Y., Terashita Y., Sugiura H., Shinoda N., Kimura M., Kuwabara Y., Fujii Y. Aberrant nuclear localization of beta-catenin without genetic alterations in beta-catenin or Axin genes in esophageal cancer. World J. Surg. Oncol. 2007, 5:21.
20. Gamallo C., Palacios J., Moreno G., Calvo de Mora J., Suárez A., Armas A. Beta-catenin expression pattern in stage I and II ovarian carcinomas: relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. Am. J. Pathol. 1999, 155:527-536.
21. Abraham S.C., Wu T.T., Hruban R.H., Lee J.H., Yeo C.J., Conlon K., Brennan M., Cameron J.L., Klimstra D.S. Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. Am. J. Pathol. 2002, 160:953-962.
22. Koesters R., von Knebel Doeberitz M. The Wnt signaling pathway in solid childhood tumors. Cancer Lett. 2003, 198:123-138.
23. Lowy A.M., Fenoglio-Preiser C., Kim O.J., Kordich J., Gomez A., Knight J., James L., Groden J. Dysregulation of beta-catenin expression correlates with tumor differentiation in pancreatic duct adenocarcinoma. Ann. Surg. Oncol. 2003, 10:284-290.
24. Al-Aynati M.M., Radulovich N., Riddell R.H., Tsao M.S. Epithelial-cadherin and beta-catenin expression changes in pancreatic intraepithelial neoplasia. Clin. Cancer Res. 2004, 10:1235-1240.
25. Zeng G., Germinaro M., Micsenyi A., Monga N.K., Bell A., Sood A., Malhotra V., Sood N., Midda V., Monga D.K., Kokkinakis D.M., Monga S.P. Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma. Neoplasia 2006, 8:279-289.
26. Chetty R., Serra S., Asa S.L. Loss of membrane localization and aberrant nuclear E-cadherin expression correlates with invasion in pancreatic endocrine tumors. Am. J. Surg. Pathol. 2008, 32:413-419.
27. Liu B.A., Li Z.M., Su Z.S., She X.L. Pathological differential diagnosis of solid-pseudopapillary neoplasm and endocrine tumors of the pancreas. World J. Gastroenterol. 2010, 16:1025-1030.
28. Kovar H., Dworzak M., Strehl S., Schnell E., Ambros I.M., Ambros P.F., Gadner H. Overexpression of the pseudoautosomal gene MIC2 in Ewing's sarcoma and peripheral primitive neuroectodermal tumor. Oncogene 1990, 15:1067-1070.
29. Rocchi A., Manara M.C., Sciandra M., Zambelli D., Nardi F., Nicoletti G., Garofalo C., Meschini S., Astolfi A., Colombo M.P., Lessnick S.L., Picci P., Scotlandi K. CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. J. Clin. Invest. 2010, 120:668-680.
30. Lee H.J., Kim E., Jee B., Hahn J.H., Han K., Jung K.C., Park S.H., Lee H. Functional involvement of src and focal adhesion kinase in CD99 splice variant-induced motility of human breast cancer cells. Exp. Mol. Med. 2002, 34:177-183.
31. Ambros I.M., Ambros P.F., Strehl S., Kovar H., Gadner H., Salzer-Kuntschik M. MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer 1991, 67(7):1886-1893.
32. Yoo Seong-Ho, Han Jungho, Kim Tae Jin, Chung Doo Hyun Expression of CD99 in pleomorphic carcinomas of the lung. J. Korean Med. Sci. 2005, 20:50-55.
33. Fellinger E.J., Garin-Chesa P., Triche T.J., Huvos A.G., Rettig W.J. Immunohistochemical analysis of Ewing's sarcoma cell surface antigen p30/32MIC2. Am. J. Pathol. 1991, 139:317-325.
34. Gordon M.D., Corless C., Renshaw A.A., Beckstead J. CD99, keratin, and vimentin staining of sex cord-stromal tumors, normal ovary, and testis. Mod. Pathol. 1998, 11:769-773.